Research and Markets: Company and Industry Analysis of the US$14.9 Billion Asia-Pacific Biotechnology Market
DUBLIN, Ireland--(Business Wire)--
Research and Markets
(http://www.researchandmarkets.com/research/4cd54f/asiapacific_biote)
has announced the addition of the "Asia-Pacific Biotechnology Sectors
: A Company and Industry Analysis (August 2008)" report to their
offering.
This report updates the previous Asia-Pacific biotechnology
report, focusing on the markets in Australia, China and Hong Kong,
India, Japan, South Korea and Taiwan
Current Environment - Key Points
- The rising cost of conducting research and carrying out trials
in the west continued to shift investment to the east over the first
half of 2008
- The stock market's decline affected biotech stocks, partly due
to their higher risk profiles compared to other stocks
The Intersuisse Biotechnology Index in Australia, for example,
reported the sharpest annual decline since its inception in 1996
- A landmark agreement between China's State Food and Drug
Administration and the US Department of Health and Human Services,
signed in Beijing in December, aimed to improve drug safety and
quality control over Chinese produced pharmaceutical and biotech
substances
- However, merger, acquisition and alliance activity remained
strong in the first half of 2008
In a major transaction, Japan's Takeda Pharmaceutical (TSE: 4502)
acquired US-based Millennium Pharmaceuticals (NASDAQ: MLNM) for US$8.8
billion in April
- Cash-rich drug makers continued to pursue acquisitions as they
tried to cushion the impact of expiring patents in the coming years
and fill out thin late-stage pipelines
Industry Profile - Key Points
- The biotech market in the Asia-Pacific was valued at US$14.9
billion for 2007 and is expected to grow by 10% in 2008, with Japan
the largest contributor
- Governments in the Asia-Pacific are still providing most of the
investment support to their biotech sectors
Currently, China is outspending the US on biotech
- Research and development (R&D) remain active in Australia, and
encompass a range of research areas
- The Indian Government is considering switching to a pentavalent
(five-in-one) vaccine in the country's immunization program, which
will benefit some Indian biotech companies in the pentavalent vaccine
business
The Government also undertook two major regulatory initiatives -
the creation of the National Biotechnology Regulatory Authority and
the Central Drug Authority
Market Trends and Outlook - Key Points
- Biotech crops, or genetically modified (GM) crops, are still
gaining ground globally
R&D work on biotech crops is widely dispersed across the
Asia-Pacific
Recently, several factors have contributed towards an increase in
grain prices worldwide, making biotech crops even more important
- The monoclonal antibodies (mAb) market is expected to grow
significantly in the next few years, boosted by the number of new mAbs
in the market, new indications for successful medications and their
ability to treat diseases
The Asia-Pacific is poised to become a dominant player in the area
of antibody therapeutics development with the region offering a number
of advantages
- Nanotechnology and biotechnology are now fusing to start a
technology revolution - nanobiotechnology - and it is taking hold in
the Asia-Pacific
Nanotech has become a main science and technology priority area
for governments throughout the region
Budgets for nanotech R&D are being more strategically allocated
- The outlook for the biotech industry in the Asia-Pacific remains
strong, with it attracting much attention in recent years
Several countries have declared their intentions to become the
biotech hubs of the region
Most attention will be on China and India, as the two countries
continue to pursue biotech advancement.
Key Topics Covered:
- Current Environment
- Sector Overview
- Sector Performance
- Leading Companies
- Mergers, Acquisitions and Alliances Industry Profile
- Industry Size and Value
- Sector Investment
- Research and Development
- Policy and Regulatory Environment Market Trends and Outlook
- Biotech Crops Gain Ground
- Human Antibodies to Dominate Next Wave of Approvals
- Nanotechnology Fuses with Biotech
- Market Outlook Country Profiles
- Australia
- China
- India
- Japan
- South Korea
- Taiwan Currency Conversion Table
- The Scope of This Report
- Key References
- Comparative Data
- Regional Reports Coverage
For more information visit
http://www.researchandmarkets.com/research/4cd54f/asiapacific_biote
Research and Markets
Laura Wood, Senior Manager
Fax from USA: 646-607-1907
Fax from rest of the world: +353-1-481-1716
press@researchandmarkets.com
Copyright Business Wire 2008
